Canine Atopic Dermatitis Treatment Drugs Market, by Drug Class (Janus Kinase Inhibitors, Immunosuppressant, Monoclonal Antibody, Antibiotics, and Others), by Route of Administration (Injection, Oral, and Topical), by Distribution Channel (Hospital and Cli

Canine Atopic Dermatitis Treatment Drugs Market, by Drug Class (Janus Kinase Inhibitors, Immunosuppressant, Monoclonal Antibody, Antibiotics, and Others), by Route of Administration (Injection, Oral, and Topical), by Distribution Channel (Hospital and Clinics, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Canine atopic dermatitis is an inflammatory, chronic skin disease associated with allergies. This is the second most common allergic skin disease in dogs. The major cause of atopic dermatitis in dogs is harmful allergen such as animal dander, airborne pollens, mold spores, and house dust. This disease in dogs is often hereditary and exposure to any harmful allergen can trigger the onset of canine atopic dermatitis. Its symptoms include excessive itching and scratching, hair loss, greasy or flaky skin with a foul odor, and excessive scratching on the paws and areas such as the groin and armpits.
Market Dynamics
The global canine atopic dermatitis treatment drugs market is expected to witness high growth over the forecast period, owing to increasing pet ownership.
However, the high cost associated with cyclosporine, glucocorticoids, immunotherapy, and oral histamines treatment therapies is a major factor restraining the global canine atopic dermatitis treatment drugs market growth. For instance, the cost of canine atopic dermatitis treatment ranges from US$ 600 to US$ 1,100 depending on the type and severity of atopic dermatitis. An additional cost of diagnostic tests, sedation for injection, and others may include more than US$ 200 to US$ 300.
Key features of the study:
This report provides an in-depth analysis of the global canine atopic dermatitis treatment drugs market, market size (US$ Mn), and compound annual growth rate (CAGR %) during the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players operating in this market
It profiles key players in the global canine atopic dermatitis treatment drugs market based on the following parameters–company overview, financial performance, product portfolio, geographical presence, key developments, and strategies.
Key players covered as a part of this study include Zoetis Inc., Elanco Animal Health Incorporated, Virbac, Kindred Biosciences, Inc., Nippon Zenyaku Kogyo Co., Ltd. (ZENOAQ), Bioiberica S.A.U, Dechra Pharmaceuticals PLC, and Toray Industries, Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global canine atopic dermatitis treatment drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for global canine atopic dermatitis treatment drugs market, research and consulting firms, new entrants, and financial analysts

Detailed Segmentation:
Global Canine Atopic Dermatitis Treatment Drugs Market, By Drug Class:
Janus Kinase Inhibitors
Immunosuppressant
Monoclonal Antibody
Antibiotics
Others
Global Canine Atopic Dermatitis Treatment Drugs Market, By Route of Administration:
Injection
Oral
Topical
Global Canine Atopic Dermatitis Treatment Drugs Market, By Distribution Channel:
Hospital and Clinics
Retail Pharmacies
Online Pharmacies
Global Canine Atopic Dermatitis Treatment Drugs Market, By Region:
North America
By Country:
U.S.
Canada
By Drug Class:
Janus kinase Inhibitors
Immunosuppressant
Monoclonal Antibody
Antibiotics
Others
By Route of Administration:
Injection
Oral
Topical
By Distribution Channel
Hospital and Clinics
Retail Pharmacies
Online Pharmacies
Europe
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
By Drug Class:
Janus kinase Inhibitors
Immunosuppressant
Monoclonal Antibody
Antibiotics
Others
By Route of Administration:
Injection
Oral
Topical
By Distribution Channel
Hospital and Clinics
Retail Pharmacies
Online Pharmacies
Asia Pacific
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
By Drug Class:
Janus kinase Inhibitors
Immunosuppressant
Monoclonal Antibody
Antibiotics
Others
By Route of Administration:
Injection
Oral
Topical
By Distribution Channel
Hospital and Clinics
Retail Pharmacies
Online Pharmacies
Latin America
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
By Drug Class:
Janus kinase Inhibitors
Immunosuppressant
Monoclonal Antibody
Antibiotics
Others
By Route of Administration:
Injection
Oral
Topical
By Distribution Channel
Hospital and Clinics
Retail Pharmacies
Online Pharmacies
Middle East
By Country:
GCC
Israel
Rest of Middle East
By Drug Class:
Janus kinase Inhibitors
Immunosuppressant
Monoclonal Antibody
Antibiotics
Others
By Route of Administration:
Injection
Oral
Topical
By Distribution Channel
Hospital and Clinics
Retail Pharmacies
Online Pharmacies
Africa
By Country/Region:
South Africa
Central Africa
North Africa
By Drug Class:
Janus kinase Inhibitors
Immunosuppressant
Monoclonal Antibody
Antibiotics
Others
By Route of Administration:
Injection
Oral
Topical
By Distribution Channel
Hospital and Clinics
Retail Pharmacies
Online Pharmacies
Company Profiles
Zoetis Inc.*
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Elanco Animal Health Incorporated
Virbac
Kindred Biosciences, Inc.
Nippon Zenyaku Kogyo Co., Ltd. (ZENOAQ)
Bioiberica S.A.U
Dechra Pharmaceuticals PLC
Toray Industries, Inc.
“*” marked represents similar segmentation in other categories in the respective section.